CN117018138A - Traditional Chinese medicine composition for treating chronic renal failure and application thereof - Google Patents

Traditional Chinese medicine composition for treating chronic renal failure and application thereof Download PDF

Info

Publication number
CN117018138A
CN117018138A CN202311097953.XA CN202311097953A CN117018138A CN 117018138 A CN117018138 A CN 117018138A CN 202311097953 A CN202311097953 A CN 202311097953A CN 117018138 A CN117018138 A CN 117018138A
Authority
CN
China
Prior art keywords
parts
traditional chinese
chinese medicine
medicine composition
renal failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202311097953.XA
Other languages
Chinese (zh)
Inventor
徐莹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yunnan Provincial Hospital of Traditional Chinese Medicine
Original Assignee
Yunnan Provincial Hospital of Traditional Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yunnan Provincial Hospital of Traditional Chinese Medicine filed Critical Yunnan Provincial Hospital of Traditional Chinese Medicine
Priority to CN202311097953.XA priority Critical patent/CN117018138A/en
Publication of CN117018138A publication Critical patent/CN117018138A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708—Rheum (rhubarb)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489—Sophora, e.g. necklacepod or mamani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/532—Agastache, e.g. giant hyssop
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/714—Aconitum (monkshood)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/746—Morinda
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/748—Oldenlandia or Hedyotis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888—Pinellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9064—Amomum, e.g. round cardamom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating chronic renal failure and application thereof. The traditional Chinese medicine composition comprises the following traditional Chinese medicine components in parts by weight: 5-20 parts of rheum officinale, 5-19 parts of fructus amomi, 80-120 parts of astragalus membranaceus, 4-23 parts of pinellia ternate, 4-20 parts of agastache rugosa, 6-25 parts of betel nuts, 8-20 parts of angelica sinensis, 12-25 parts of achyranthes bidentata, 5-23 parts of earthworm, 25-40 parts of oyster, 23-40 parts of oldenlandia diffusa, 25-40 parts of semen plantaginis, 25-35 parts of pyrrosia lingua, 8-15 parts of aconite, 7-20 parts of morinda officinalis, 10-20 parts of ginseng, 10-20 parts of sophora japonica and 80-120 parts of glabrous greenbrier rhizome. The invention also provides an application method of the traditional Chinese medicine composition in preparing a medicine for treating chronic renal failure.

Description

Traditional Chinese medicine composition for treating chronic renal failure and application thereof
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating chronic renal failure and application thereof.
Background
Chronic Renal Failure (CRF) refers to a clinical syndrome in which the kidney is obviously atrophic and fails to maintain basic functions due to chronic progressive renal parenchymal injury caused by various causes, and the clinical manifestations are metabolic product retention, imbalance of water, electrolytes and acid and base, and the system involvement of the whole body. The main causes are primary glomerulonephritis, chronic pyelonephritis, hypertension renal arteriole sclerosis, diabetic nephropathy, secondary glomerulonephritis, tubular interstitial lesions, hereditary renal diseases, long-term administration of antipyretic analgesic and heavy metal exposure, etc.
The incidence rate of chronic kidney disease in China is 10.8%, wherein 67% of patients have serious damage to kidney function at the initial diagnosis, and 10% have progressed to the end stage of chronic kidney failure. At this time, metabolic waste and excessive water in the body cannot be discharged, erythropoietin secretion is reduced, calcium and phosphorus metabolism is disturbed, uremic toxin accumulation, sodium retention, anemia, bone diseases and other symptoms appear, and the uremia is called, so that the life and the health of human beings are seriously endangered.
The western medicine mainly adopts hormone therapy for treating the chronic renal failure, but the hormone therapy only can relieve temporary illness and has obvious side effects and easy recurrence, but the traditional Chinese medicine is otherwise obvious in effect, difficult to recur and free of pain and side effects, so that the traditional Chinese medicine has great advantages for treating the chronic renal failure at present.
Chronic renal failure can be regarded as a clinical common disease at present, but the treatment effect is not ideal, and no effective medicine capable of curing chronic renal failure exists in the prior art at present. Therefore, the traditional Chinese medicine for promoting the recovery of patients with chronic renal failure, improving the life quality and prolonging the life span has important social significance.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a traditional Chinese medicine composition for treating chronic renal failure and application thereof.
In order to achieve the above purpose, the technical scheme provided by the invention is as follows:
a traditional Chinese medicine composition for treating chronic renal failure comprises the following raw materials in parts by weight: 5-20 parts of rheum officinale, 5-19 parts of fructus amomi, 80-120 parts of astragalus membranaceus, 4-23 parts of pinellia ternate, 4-20 parts of agastache rugosa, 6-25 parts of betel nuts, 8-20 parts of angelica sinensis, 12-25 parts of achyranthes bidentata, 5-23 parts of earthworms, 25-40 parts of oyster, 23-40 parts of oldenlandia diffusa, 25-40 parts of semen plantaginis, 25-35 parts of pyrrosia lingua, 8-15 parts of aconite, 7-20 parts of morinda officinalis and 10-20 parts of ginseng.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 15 parts of rheum officinale, 15 parts of fructus amomi, 100 parts of astragalus membranaceus, 15 parts of pinellia ternate, 15 parts of wrinkled gianthyssop herb, 15 parts of betel nut, 10 parts of Chinese angelica, 15 parts of achyranthes root, 15 parts of earthworm, 30 parts of oyster, 30 parts of oldenlandia diffusa, 30 parts of semen plantaginis, 30 parts of pyrrosia lingua, 10 parts of aconite, 15 parts of morinda officinalis and 15 parts of ginseng.
Further, the traditional Chinese medicine composition further comprises the following components in parts by weight: 10-20 parts of pagodatree flower and 80-120 parts of glabrous greenbrier rhizome.
Preferably, the traditional Chinese medicine composition further comprises the following components in parts by weight: 15 parts of pagodatree flower and 100 parts of glabrous greenbrier rhizome.
Further, the traditional Chinese medicine composition for treating chronic renal failure can be prepared into powder, pills and decoction.
The invention also provides a method for preparing the traditional Chinese medicine composition for treating chronic renal failure into powder, which comprises the following steps:
(1) weighing the following traditional Chinese medicine components in parts by weight: soaking 5-19 parts of grass nuts, 12-25 parts of achyranthes bidentata, 5-23 parts of earthworms and 25-40 parts of oyster in rice swill for 10 minutes, stir-frying the Chinese herbal medicines with slow fire, adding white spirit while stir-frying until the mass of the added white spirit is 0.5 times of the mass of the Chinese herbal medicines, taking out, cooling to room temperature, and grinding into fine powder;
(2) weighing the following traditional Chinese medicine components in parts by weight: 5-20 parts of rheum officinale, 80-120 parts of astragalus membranaceus, 4-23 parts of pinellia ternate, 4-20 parts of agastache rugosa, 6-25 parts of betel nut, 8-20 parts of Chinese angelica, 23-40 parts of oldenlandia diffusa, 25-40 parts of semen plantaginis, 25-35 parts of pyrrosia lingua, 10-20 parts of sophora flower, 80-120 parts of smilax glabra, 8-15 parts of aconite, 7-20 parts of morinda officinalis and 10-20 parts of ginseng, and the components are placed in a closed container for steaming and boiling, then steaming for half an hour with slow fire, taking out the steamed traditional Chinese medicines, cooling, drying at 50 ℃, grinding the traditional Chinese medicines into fine powder, mixing the obtained fine powder with the fine powder treated in the step (1), and sieving the mixture with 120 meshes to obtain the traditional Chinese medicine composition.
The beneficial effects are that:
the traditional Chinese medicine composition provided by the invention comprises traditional Chinese medicine components with the effects of drying dampness and strengthening spleen, promoting diuresis and treating stranguria, clearing heat and detoxicating, tonifying fire and supporting yang, the pathological environment of the kidney is improved from multiple aspects, the renal cell renewal is promoted, and the treatment effective rate of chronic renal failure patients with blood creatinine within 300 mu mol/L is 80% through years of clinical treatment observation.
The traditional Chinese medicine composition is added with traditional Chinese medicine components such as wrinkled giant hyssop, pagodatree flower and the like which have the effects of seasoning and tonifying qi, so that the bitter taste of the traditional Chinese medicine composition is improved, and the taste pain of a user is reduced.
The application method processes the traditional Chinese medicine composition according to the physicochemical properties and pharmacological actions of the traditional Chinese medicine components, fully plays the medicinal actions of the components, and increases the stability of the medicinal effect.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention more clear, the technical solutions in the embodiments of the present invention will be clearly and completely described below in connection with the embodiments of the present invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1
A traditional Chinese medicine composition for treating chronic renal failure comprises the following traditional Chinese medicine components in parts by weight: 5-20 parts of rheum officinale, 5-19 parts of fructus amomi, 80-120 parts of astragalus membranaceus, 4-23 parts of pinellia ternate, 4-20 parts of agastache rugosa, 6-25 parts of betel nuts, 8-20 parts of angelica sinensis, 12-25 parts of achyranthes bidentata, 5-23 parts of earthworms, 25-40 parts of oyster, 23-40 parts of oldenlandia diffusa, 25-40 parts of semen plantaginis, 25-35 parts of pyrrosia lingua, 8-15 parts of aconite, 7-20 parts of morinda officinalis and 10-20 parts of ginseng.
The preparation method of the traditional Chinese medicine composition powder for treating chronic renal failure comprises the following steps:
(1) weighing the following traditional Chinese medicine components in parts by weight: soaking 5-19 parts of grass nuts, 12-25 parts of achyranthes bidentata, 5-23 parts of earthworms and 25-40 parts of oyster in rice swill for 10 minutes, stir-frying the Chinese herbal medicines with slow fire, adding white spirit while stir-frying until the mass of the added white spirit is 0.5 times of the mass of the Chinese herbal medicines, taking out, cooling to room temperature, and grinding into fine powder;
(2) weighing the following traditional Chinese medicine components in parts by weight: 5-20 parts of rheum officinale, 80-120 parts of astragalus membranaceus, 4-23 parts of pinellia ternate, 4-20 parts of agastache rugosa, 6-25 parts of betel nut, 8-20 parts of Chinese angelica, 23-40 parts of oldenlandia diffusa, 25-40 parts of semen plantaginis, 25-35 parts of pyrrosia lingua, 8-15 parts of aconite, 7-20 parts of morinda officinalis and 10-20 parts of ginseng, placing the materials in a closed container for steaming, continuously steaming with small fire for half an hour after boiling, taking out the steamed traditional Chinese medicines, cooling the steamed traditional Chinese medicines, drying the steamed traditional Chinese medicines at 50 ℃, grinding the steamed traditional Chinese medicines into fine powder, mixing the obtained fine powder with the fine powder treated in the step (1), and sieving the mixture with a 120-mesh sieve to obtain the traditional Chinese medicine composition powder for treating chronic renal failure.
The taking method of the powder obtained by the invention is as follows: three times per day, 0.5g of boiled water is weighed each time, and the medicine is taken after 40 days as a treatment course.
The first embodiment shows the component content of the traditional Chinese medicine composition for treating chronic renal failure and the preparation method of the powder of the traditional Chinese medicine composition. According to different biochemical properties and pharmacological effects of different traditional Chinese medicine components, parching and steaming methods are selected to obtain cooked traditional Chinese medicine mixture powder. The obtained powder is administered by flushing, and toxic components in the Chinese medicinal materials are removed while retaining active ingredients exerting medicinal effects.
Example two
A traditional Chinese medicine composition for treating chronic renal failure comprises the following traditional Chinese medicine components in parts by weight: 5-20 parts of rheum officinale, 5-19 parts of fructus amomi, 80-120 parts of astragalus membranaceus, 4-23 parts of pinellia ternate, 4-20 parts of agastache rugosa, 6-25 parts of betel nuts, 8-20 parts of angelica sinensis, 12-25 parts of achyranthes bidentata, 5-23 parts of earthworms, 25-40 parts of oyster, 23-40 parts of oldenlandia diffusa, 25-40 parts of semen plantaginis, 25-35 parts of pyrrosia lingua, 8-15 parts of aconite, 7-20 parts of morinda officinalis and 10-20 parts of ginseng.
The preparation method of the traditional Chinese medicine composition powder for treating chronic renal failure comprises the following steps:
(1) weighing the following traditional Chinese medicine components in parts by weight: soaking 5-19 parts of grass nuts, 12-25 parts of achyranthes bidentata, 5-23 parts of earthworms and 25-40 parts of oyster in rice swill for 10 minutes, stir-frying the Chinese herbal medicines with slow fire, adding white spirit while stir-frying until the mass of the added white spirit is 0.5 times of the mass of the Chinese herbal medicines, taking out, cooling to room temperature, and grinding into fine powder;
(2) weighing the following traditional Chinese medicine components in parts by weight: 10-20 parts of pagodatree flower, 80-120 parts of glabrous greenbrier rhizome, 5-20 parts of rhubarb, 80-120 parts of astragalus, 4-23 parts of pinellia tuber, 4-20 parts of wrinkled giant hyssop, 6-25 parts of betel nut, 8-20 parts of Chinese angelica, 23-40 parts of oldenlandia diffusa, 25-40 parts of plantain seed, 25-35 parts of pyrrosia lingua, 8-15 parts of aconite root, 7-20 parts of morinda officinalis and 10-20 parts of ginseng, and the steps of steaming in a closed container, continuing steaming with slow fire for half an hour after boiling water, taking out the steamed traditional Chinese medicine materials, cooling, drying at 50 ℃, grinding the dried traditional Chinese medicine materials into fine powder, mixing the obtained fine powder with the fine powder treated in the step (1), and sieving the mixture with 120 meshes to obtain the traditional Chinese medicine composition powder for treating chronic renal failure.
The taking method of the powder obtained by the invention is as follows: three times per day, 1.2g of boiled water is weighed each time, and is taken after 40 days as a treatment course.
Example two shows the preparation of the Chinese medicinal composition containing flos Sophorae Immaturus and rhizoma Smilacis Glabrae for treating chronic renal failure and its powder. Compared with the traditional Chinese medicine composition displayed in the first embodiment, the traditional Chinese medicine composition in the second embodiment is added with two medicinal materials of sophora flower and glabrous greenbrier rhizome, so that the effects of clearing heat, detoxicating and promoting urination are enhanced, and the medicinal effect is stronger.
Example III
Animal experiment:
1. experimental animal
Source, germ line, strain: wistar male rats weighing 180-220g, male animals were kept in laboratory animal experiment barrier system of the first affiliated hospital center of Yunnan Chinese medical institute, and the laboratory animals were used after at least one week of keeping. The temperature is 22+/-1 ℃, the humidity is 55+/-5 percent, and the light and dark cycle is carried out for 12 hours. Both feed and water are freely ingested by the animal after sterilization. All experiments were performed strictly in accordance with the relevant regulations of the experimental animals.
2. Experimental method and index detection
2.1 establishment and grouping of the rat model for chronic renal failure
A chronic renal failure rat model is established by adopting one-time tail vein puromycin aminonucleoside induction, and the specific method is as follows: a single 100mg/kg injection of puromycin aminonucleoside was selected to induce the establishment of a chronic renal failure rat model. The urine protein is obviously higher than that of a normal control group in 24 hours, and the statistical difference has obvious significance and is successfully modeled.
2.2 grouping and administration
Rats with successful models are divided into a chronic renal failure model group and a low, medium and high administration group of large-yellow strawberries decoction according to 24h urine protein level, 8 rats in each group are provided with 8 normal control groups. The low, medium and high administration groups of the large-yellow-fruit astragalus decoction are respectively subjected to intragastric administration in doses of 4g/kg, 12g/kg and 36g/kg, normal control combined pathological model group is subjected to intragastric administration of equal-dose physiological saline, the administration doses are calculated according to a conversion formula of the administration doses of experimental animals and human, and index detection is carried out on 7 days, 28 days and 42 days respectively.
2.3 index detection
2.3.1 urine protein and urine creatinine (Cr) detection
At the observation point, the rats are fasted and not forbidden, the urine is collected for 24 hours by using a metabolism cage, 1ml of urine is taken after the urine volume is recorded, 5000r/m of urine is taken, after sediment is removed, the content of urine protein is detected by adopting a Coomassie brilliant blue method, and the urine creatinine level is detected.
Urine protein and urine creatinine (Cr) assays
k blank group, M model group, Y positive group, D low dose group, Z medium dose group, G high dose group;
y positive group
Dose group in Z
G high dose group
D Low dose group
k blank group
M model group
The foregoing description of the preferred embodiments of the present invention is not intended to be limiting, but rather, although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that modifications may be made to the embodiments described, or equivalents may be substituted for elements thereof, and any modifications, equivalents, improvements or changes may be made without departing from the spirit and principles of the present invention.

Claims (5)

1. A traditional Chinese medicine composition for treating chronic renal failure is characterized in that: the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 5-20 parts of rheum officinale, 5-19 parts of fructus amomi, 80-120 parts of astragalus membranaceus, 4-23 parts of pinellia ternate, 4-20 parts of agastache rugosa, 6-25 parts of betel nuts, 8-20 parts of angelica sinensis, 12-25 parts of achyranthes bidentata, 5-23 parts of earthworms, 25-40 parts of oyster, 23-40 parts of oldenlandia diffusa, 25-40 parts of semen plantaginis, 25-35 parts of pyrrosia lingua, 8-15 parts of aconite, 7-20 parts of morinda officinalis and 10-20 parts of ginseng.
2. The traditional Chinese medicine composition for treating chronic renal failure according to claim 1, wherein: the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 15 parts of rheum officinale, 15 parts of fructus amomi, 100 parts of astragalus membranaceus, 15 parts of pinellia ternate, 15 parts of wrinkled gianthyssop herb, 15 parts of betel nut, 10 parts of Chinese angelica, 15 parts of achyranthes root, 15 parts of earthworm, 30 parts of oyster, 30 parts of oldenlandia diffusa, 30 parts of semen plantaginis, 30 parts of pyrrosia lingua, 10 parts of aconite, 15 parts of morinda officinalis and 15 parts of ginseng.
3. The traditional Chinese medicine composition for treating chronic renal failure according to claim 1 or claim 2, characterized in that: the traditional Chinese medicine composition also comprises the following components: 10-20 parts of pagodatree flower and 80-120 parts of glabrous greenbrier rhizome.
4. The traditional Chinese medicine composition for treating chronic renal failure according to claim 3, wherein: 15 parts of sophora flower and 100 parts of smilax glabra.
5. The method for preparing the powder of the traditional Chinese medicine composition for treating chronic renal failure according to any one of claims 1 to 4, which is characterized in that: the preparation steps are as follows:
(1) weighing the following traditional Chinese medicine components in parts by weight: soaking 5-19 parts of grass nuts, 12-25 parts of achyranthes bidentata, 5-23 parts of earthworms and 25-40 parts of oyster in rice swill for 10 minutes, stir-frying the Chinese herbal medicines with slow fire, adding white spirit while stir-frying until the mass of the added white spirit is 0.5 times of the mass of the Chinese herbal medicines, taking out, cooling to room temperature, and grinding into fine powder;
(2) weighing the following traditional Chinese medicine components in parts by weight: 5-20 parts of rheum officinale, 80-120 parts of astragalus membranaceus, 4-23 parts of pinellia ternate, 4-20 parts of agastache rugosa, 6-25 parts of betel nut, 8-20 parts of Chinese angelica, 23-40 parts of oldenlandia diffusa, 25-40 parts of semen plantaginis, 25-35 parts of pyrrosia lingua, 8-15 parts of aconite, 10-20 parts of sophora japonica, 80-120 parts of glabrous greenbrier rhizome, 7-20 parts of morinda officinalis and 10-20 parts of ginseng, and placing the materials into a closed container for steaming, steaming with slow fire for half an hour after boiling, taking out the steamed Chinese medicinal materials, and placing the Chinese medicinal materials
Cooling, drying at 50 ℃, grinding into fine powder, mixing the obtained fine powder with the fine powder treated in the step (1),
sieving with 120 mesh sieve to obtain Chinese medicinal composition powder for treating chronic renal failure.
CN202311097953.XA 2023-08-29 2023-08-29 Traditional Chinese medicine composition for treating chronic renal failure and application thereof Withdrawn CN117018138A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311097953.XA CN117018138A (en) 2023-08-29 2023-08-29 Traditional Chinese medicine composition for treating chronic renal failure and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202311097953.XA CN117018138A (en) 2023-08-29 2023-08-29 Traditional Chinese medicine composition for treating chronic renal failure and application thereof

Publications (1)

Publication Number Publication Date
CN117018138A true CN117018138A (en) 2023-11-10

Family

ID=88631676

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202311097953.XA Withdrawn CN117018138A (en) 2023-08-29 2023-08-29 Traditional Chinese medicine composition for treating chronic renal failure and application thereof

Country Status (1)

Country Link
CN (1) CN117018138A (en)

Similar Documents

Publication Publication Date Title
WO2007009291A1 (en) A pharmaceutical composition of traditional chineses medicine for treating rheumatoid arthritis and preparation thereof
CN108853433A (en) A kind of Chinese medicine and preparation method thereof for treating diabetic nephropathy
CN113713039A (en) Traditional Chinese medicine composition for treating membranous nephropathy and application thereof
CN103989970A (en) Traditional Chinese medicine composition and application thereof in preparation of medicines for treating hypertension
CN102106980B (en) Medicament for treating uremia and preparation method thereof
CN103735927A (en) Traditional Chinese medicinal composition for treating acute stage of gout and preparation method thereof
CN109078156A (en) It is a kind of to treat calculi in urinary system Chinese medicine and preparation method thereof
CN117018138A (en) Traditional Chinese medicine composition for treating chronic renal failure and application thereof
CN103585495B (en) Capsule for treating diabetic kidney damage
CN105998900A (en) Traditional Chinese medicine for treating gout and hyperuricemia and preparing method thereof
CN106039131A (en) Traditional Chinese medicinal compound preparation for treating IgA nephrosis with hyperuricemia, and preparation method and use thereof
CN105327267A (en) Traditional Chinese medicine liquor for treating tumors and preparation method of traditional Chinese medicine liquor for treating tumors
CN106138494B (en) Kidney nourishing composition and production method thereof
CN1166972A (en) Green powder medicine for discharging calculus stone
CN108743885A (en) A kind of Chinese medicine and preparation method thereof for treating Diabetic Macrovascular Complications
CN110870894A (en) Traditional Chinese medicine composition for treating diarrhea
CN105687365A (en) Traditional Chinese medicine composition for treating polymyositis and preparation method and application of traditional Chinese medicine composition for treating polymyositis
CN104069284A (en) Traditional Chinese medicine preparation for treating calculus
CN103656355B (en) Medicine being used for the treatment of swine paratyphoid and preparation method thereof
CN108210595A (en) Treat Chinese medicine composition of acute-on-chronic liver failure and its preparation method and application
CN107929619A (en) Lotion for gynaecological imflammation and preparation method thereof
CN106236971A (en) A kind of Chinese medicine composition treating chronic nephritis
CN105998453A (en) Traditional Chinese medicine for treating gout and hyperuricemia
CN108853380B (en) Pharmaceutical composition for treating diabetes and preparation method and application thereof
CN108721572B (en) A Chinese medicinal composition for treating hepatocarcinoma and liver cirrhosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20231110